

Ref: GLL/BSE/2023/Feb-05

Date: February 14, 2023

To
Corporate Relations Manager
BSE Limited
Phiroje Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

To
Listing Manager
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex,
Opposite Sahajanand College,
120 Feet Ring Rd, Panjara Pol, Ambawadi,
Ahmedabad – 380 015

To
The Secretary
The Calcutta Stock Exchange Limited
#7, Lyons Range, Murgighata,
Dalhousie, Kolkata – 700 001

Sub: Outcome of the Board Meeting held on February 14, 2023 of Gennex Laboratories Limited
Ref: Regulation 29, 33 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

In just concluded Meeting of the Board Directors of the Company, the board has considered and approved:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine Months ended December 31, 2022 (annexed herewith);
3. Acceptance of Resignation of Mr. Rajesh Vankadara, as company secretary & Compliance officer of the Company.

This intimation is also uploaded in the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

For Gennex Laboratories Limited





Arihant Baid
Managing Director
DIN #01171845

Gennex Laboratories Limited



GENNEX LABORATORIES LIMITED
REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2022
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com
CIN: L24230TG1990PLC011168

PART - I							
Statement of standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2022							
(Rs. in lakhs)							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	1389.59	1911.30	1650.50	4694.62	4103.58	6121.38
	(b) Other operating Income	72.84	50.99	17.81	181.19	33.82	138.14
	Total Income from operations (net)	1462.43	1962.29	1668.31	4875.81	4137.40	6259.52
2	Expenses						
	(a) Cost of material consumed	1248.45	1096.80	1130.89	3585.67	2652.13	4001.04
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-454.59	181.91	78.33	-695.90	-125.25	-190.72
	(d) Employee benefit expense	196.55	190.60	141.95	573.01	490.22	696.86
	(f) Finance Cost	18.42	35.91	14.29	72.22	53.50	87.74
	(g) Depreciation and amortisation expense	18.73	9.54	19.01	54.67	59.26	78.85
	(h) Other expenses	289.91	307.71	183.65	900.71	626.64	1076.39
	Total expenses	1317.48	1822.47	1568.12	4490.39	3756.50	5750.17
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	144.95	139.82	100.19	385.42	380.90	509.35
4	Exceptional items	0.00	0.00	0	0.00	0.00	0.00
5	Profit(+)/Loss(-) before tax (3+4)	144.95	139.82	100.19	385.42	380.90	509.35
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	0
7	Current Tax	-36.48	-35.19	-21.22	-97.00	-95.88	-132.00
8	Deferred tax(benefit/expense)						14.97
9	Total Tax expense	-36.48	-35.19	-21.22	-97.00	-95.88	-117.03
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	108.47	104.63	78.97	288.42	285.02	392.32
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	108.47	104.63	78.97	288.42	285.02	392.32
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	18.22
18	Net profit(loss) for period	108.47	104.63	78.97	288.42	285.02	410.54

19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1611.16	1265.03	1265.03	1611.16	1265.03	1265.03
	Other Equity						3134.74
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.067	0.083	0.062	0.179	0.225	0.325
	(b) Diluted	0.067	0.083	0.062	0.179	0.225	0.325

Standalone Notes:

1. The standalone unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.

2. The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on February 14, 2023. The Statutory auditors have carried out limited review of the above results for the quarter and nine months ended December 31, 2022. An unmodified report has been issued by them thereon.

3. During the Quarter Company called the partly shareholders who are subscribed pursuant to the offer letter dated June 30, 2022 to honour the First and Final call money notice dated October 11, 2022. 3,46,13,043 partly paid equity shares are converted to fully paid equity shares out of 5,25,06,534 partly paid equity shares.


4. The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.

5. Previous period's figures have been rearranged / regrouped wherever necessary

6. The quarterly unaudited standalone financial results for the Quarter and Nine Months ended December 31, 2022 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited


Arihant Baid
 Managing Director
 DIN #01171845



Date: 14.02.2023
 Place: Hyderabad

Limited Review report on Unaudited Standalone Quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter ended December 31, 2022 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed tire information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are

5-8-352, 701 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.
Ph: +91-40-28205049, 66132176, 48517622 email : giri@ppkg.com www.batgach.com


Branch Office : VIJAYAWADA

Associate Office at : AHMEDABAD • BENGALURU • CHENNAI • DELHI • GUWAHATI • JAIPUR • KOLKATA • MUMBAI • SILCHAR (ASSAM) • TRIVANDRUM

subject to confirmations/reconciliations. Advances has been paid/received to/from various parties; the details, confirmations/reconciliations/purpose are yet to be provided.

The impact of the above is unascertainable. Subject to stated above, our conclusion on the Statement is not modified.

For PPKG & Co.
Chartered Accountants
FRN No. 009655S



Girdhari Lal Toshniwal
(Partner)
M. No.: 205140
UDIN: 23205140BGUNGU7841




Place: Hyderabad
Date: 14-02-2023



GENNEX LABORATORIES LIMITED
REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2022
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com
CIN: L24230TG1990PLC011168

PART - I							
Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2022							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	1389.59	1911.30	1650.50	4694.62	4103.58	6121.38
	(b) Other operating Income	72.84	50.99	17.81	181.19	33.82	138.14
	Total Income from operations (net)	1462.43	1962.29	1668.31	4875.81	4137.40	6259.52
2	Expenses						
	(a) Cost of material consumed	1248.45	1096.80	1130.89	3585.67	2652.13	4001.04
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-454.59	181.91	78.33	-695.90	-125.25	-190.72
	(d) Employee benefit expense	196.55	190.60	141.95	573.01	490.22	696.86
	(f) Finance Cost	18.42	35.91	14.29	72.22	53.50	87.74
	(g) Depreciation and amortisation expense	18.73	9.54	19.01	54.67	59.26	78.85
	(h) Other expenses	289.91	307.71	183.65	900.71	626.64	1076.39
	Total expenses	1317.48	1822.47	1568.12	4490.39	3756.50	5750.17
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	144.95	139.82	100.19	385.42	380.90	509.35
4	Exceptional items	0.00	0.00	0	0.00	0.00	0.00
5	Profit(+)/Loss(-) before tax (3+4)	144.95	139.82	100.19	385.42	380.90	509.35
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	0
7	Current Tax	-36.48	-35.19	-21.22	-97.00	-95.88	-132.00
8	Deferred tax(benefit/expense)						14.97
9	Total Tax expense	-36.48	-35.19	-21.22	-97.00	-95.88	-117.03
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	108.47	104.63	78.97	288.42	285.02	392.32
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	108.47	104.63	78.97	288.42	285.02	392.32
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	18.22




18	Net profit(loss) for period	108.47	104.63	78.97	288.42	285.02	410.54
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share) Other Equity	1611.16	1265.03	1265.03	1611.16	1265.03	1265.03 3134.74
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.067	0.083	0.062	0.179	0.225	0.325
	(b) Diluted	0.067	0.083	0.062	0.179	0.225	0.325

Consolidated Notes:

1. The Consolidated unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
2. The above Consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on February 14, 2023. The Statutory auditors have carried out limited review of the above results for the quarter and nine months ended December 31, 2022. An unmodified report has been issued by them thereon.
3. During the Quarter Company called the partly shareholders who are subscribed pursuant to the offer letter dated June 30, 2022 to honour the First and Final call money notice dated October 11, 2022. 3,46,13,043 partly paid equity shares are converted to fully paid equity shares out of 5,25,06,534 partly paid equity shares.
4. The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
5. Previous period's figures have been rearranged / regrouped wherever necessary
6. The quarterly unaudited Consolidated financial results for the Quarter and Nine Months ended December 31, 2022 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited


Arihant Baid
 Managing Director
 DIN #01171845



Date: 14.02.2023
 Place: Hyderabad

Limited Review Report On Consolidated Unaudited Quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Gennex Laboratories Limited** ("the Company") and its share of the net Profit/Loss after tax and total comprehensive income of its associates for the quarter ended December 31, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter ended December 31, 2022 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of **Deccan Remedies Limited. (Associate Company).**



Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are subject to confirmations/reconciliations. Advances has been paid/received to/from various parties; the details, confirmations/reconciliations/purpose are yet to be provided. The impact of above matters is unascertainable. Our Conclusion is not modified in respect of these matter

The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 0.00 lakhs, total net Profit after tax of Rs. 0.00 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended December 31, 2022 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management.

Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For PPKG & Co

Chartered Accountants

FRN No. 009655S

Girdhari Lal Toshniwal



Girdhari Lal Toshniwal

(Partner)

M. No.: 205140

UDIN: 23205140BGUNGV4370

Place: Hyderabad

Date: 14-02-2023